FDA面临关于广受欢迎的肽类药物的授权决定，存在安全性和有效性担忧

本文如何被排名

Signal score

0 / 100

Composite score across the factors below. Higher = stronger signal that this story matters right now.

Newsworthiness bucket

Research

文章讨论了FDA的一项重大监管决定，该决定对广受欢迎但未经证实的肽类药物具有重大的财务影响和公共卫生方面的担忧。[lever_c_demoted from significant: ic=1 ai=0.4]

Source corroboration

Single-source cluster

Only one publisher covered this so far. Single-source stories can still rank when the publisher is high-authority, but they lack cross-source corroboration.

Topics

policy, product

Editorial topic classification. Feeds into how the story surfaces on /topic/<slug> hub pages and into the per-entity coverage mix.

AI-industry relevance

Standard

On-topic for AI-industry coverage; kept in the public index.

Story freshness

59 days old

Aged out of breaking-news scoring windows; ranking reflects the durable signal from the full source set.

完整方法见我们的编辑标准。